Silexion Therapeutics (SLXN) Other Accumulated Expenses (2023 - 2026)

Silexion Therapeutics' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $3.2 million for Q2 2025.

• In Q2 2025, Other Accumulated Expenses changed N/A year-over-year to $3.2 million; the TTM figure through Jun 2025 stood at $3.2 million (changed N/A YoY), while the FY2024 annual figure was $2000.0, down 99.0% from the prior year.
• Other Accumulated Expenses for Q2 2025 stood at $3.2 million, up from $3.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.2 million in Q2 2025, with the low at $2000.0 in Q4 2024.
• The 3-year median for Other Accumulated Expenses is $200000.0 (2023), against an average of $990142.9.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses tumbled 99.0% in 2024, then surged 965.12% in 2025.
• Silexion Therapeutics' Other Accumulated Expenses stood at $200000.0 in 2023, then sank by 99.0% to $2000.0 in 2024, then surged by 159400.0% to $3.2 million in 2025.
• Business Quant data shows SLXN's Other Accumulated Expenses at $3.2 million in Q2 2025, $3.0 million in Q1 2025, and $2000.0 in Q4 2024.